UroGen Pharma Ltd Total Liabilities
UroGen Pharma Ltd total liabilities. Based on the latest financial reports, UroGen Pharma Ltd (URGN) has total liabilities worth $384.99 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check URGN cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of UroGen Pharma Ltd (2013–2025)
Total liabilities of UroGen Pharma Ltd from 2013 to 2025. This chart illustrates how UroGen Pharma Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore URGN long-term asset investment ratio to see how much of total assets are deployed in long-term investments.
UroGen Pharma Ltd Competitors by Total Liabilities
The table below lists competitors of UroGen Pharma Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Inox Wind Limited
NSE:INOXWIND
|
India | Rs-76.92 Billion |
|
Shenzhen Zhenye Group Co Ltd
SHE:000006
|
China | CN¥11.09 Billion |
|
United Corporations Limited
TO:UNC
|
Canada | CA$154.84 Million |
|
Zotye Automobile Co Ltd
SHE:000980
|
China | CN¥3.19 Billion |
|
Shandong Bailong Chuangyuan Bio-Tech Co. Ltd.
SHG:605016
|
China | CN¥717.55 Million |
|
Forestar Group Inc
NYSE:FOR
|
USA | $1.35 Billion |
|
PagSeguro Digital Ltd
NYSE:PAGS
|
USA | $59.92 Billion |
|
Universal Insurance Holdings Inc
NYSE:UVE
|
USA | $2.67 Billion |
Liability Composition Analysis (2013–2025)
This chart breaks down UroGen Pharma Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see URGN current and non-current assets.
Liquidity & Leverage Metrics
UroGen Pharma Ltd Total Liabilities Ratios Explained
UroGen Pharma Ltd total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.80 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -2.91 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.52 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how UroGen Pharma Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for UroGen Pharma Ltd (2013–2025)
The table below shows the annual total liabilities of UroGen Pharma Ltd from 2013 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $305.93 Million | +3.88% |
| 2024-12-31 | $294.51 Million | +20.94% |
| 2023-12-31 | $243.52 Million | +8.24% |
| 2022-12-31 | $224.98 Million | +102.08% |
| 2021-12-31 | $111.33 Million | +334.05% |
| 2020-12-31 | $25.65 Million | +16.14% |
| 2019-12-31 | $22.09 Million | +64.03% |
| 2018-12-31 | $13.46 Million | +91.40% |
| 2017-12-31 | $7.04 Million | +4.24% |
| 2016-12-31 | $6.75 Million | +201.70% |
| 2015-12-31 | $2.24 Million | +151.07% |
| 2014-12-31 | $891.00K | +84.09% |
| 2013-12-31 | $484.00K | -- |
About UroGen Pharma Ltd
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder… Read more